Eagle Pharmaceuticals, Inc. (EGRX)
NASDAQ: EGRX · IEX Real-Time Price · USD
+0.010 (0.21%)
May 17, 2024, 4:00 PM EDT - Market closed

Company Description

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.

The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.

The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.

It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas.

Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals logo
Country United States
Founded 2007
IPO Date Feb 12, 2014
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 134
CEO Michael Graves

Contact Details

50 Tice Boulevard, Suite 315
Woodcliff Lake, New Jersey 07677
United States
Phone 201-326-5300
Website eagleus.com

Stock Details

Ticker Symbol EGRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000827871
CUSIP Number 269796108
ISIN Number US2697961082
SIC Code 2834

Key Executives

Name Position
Michael Graves Interim Principal Executive Officer and Executive Chairman of the Board
Steven B. Ratoff Interim Chief Financial Officer, Principal Accounting Officer and Director
Daniel O'Connor Executive Vice President, Chief Strategy Officer and Head of Corporate Development
Dr. Valentin R. Curt M.D. Senior Vice President of Clinical Drug Development
Dr. Gaozhong Zhu Ph.D. Senior Vice President of Pharmaceutical Development
Debra M. Hussain Senior Vice President and Head of Commercial
Reed McClung Executive Vice President of Oncology Business Development

Latest SEC Filings

Date Type Title
May 15, 2024 8-K Current Report
May 10, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Apr 12, 2024 8-K Current Report
Mar 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 18, 2024 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 8, 2024 8-K Current Report
Mar 1, 2024 8-K Current Report
Feb 29, 2024 8-K Current Report
Feb 14, 2024 SC 13D General statement of acquisition of beneficial ownership
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals